Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab

• প্রধান লেখক: Nassim Djebli (লেখক), Neil Parrott (লেখক), Felix Jaminion (লেখক), Amaury O'Jeanson (লেখক), Elena Guerini (লেখক), David Carlile (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2024-03-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Glofitamab is a novel T cell bispecific antibody developed for treatment of relapsed‐refractory diffuse large B cell lymphoma and other non‐Hodgkin's lymphoma indications. By simultaneously binding human CD20‐expressing tumor cells and CD3 on T cells, glofitamab induces tumor cell lysi...